Nira Biosciences
Nira Biosciences is a biotechnology subsidiary of Alys Pharmaceuticals developing an antibody-targeted photo-immunotherapy platform for treating inflammatory skin disorders, serving dermatology patients and providers.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
Nira Biosciences firmographics
Firmographics- Name
- Nira Biosciences
- Legal name
- Nira Biosciences
- Website
- https://nirabio.com
- Company type
- Private
- Operating status
- Acquired
- Short description
- Nira Biosciences is a biotechnology subsidiary of Alys Pharmaceuticals developing an antibody-targeted photo-immunotherapy platform for treating inflammatory skin disorders, serving dermatology patients and providers.
- Ownership category
- akta.pro rank
Nira Biosciences industry classification
Industry- Product category
- Dermatology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Nira Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel
Nira Biosciences product offering
Product offeringCore offering
Nira Biosciences develops a biotechnology platform for antibody-targeted photo-immunotherapy treatments aimed at inflammatory skin disorders. The platform combines antibody targeting with photo-immunotherapy to deliver therapeutic intervention for dermatologic inflammatory conditions. As a fully owned subsidiary of Alys Pharmaceuticals, the company focuses on advancing this single-indication dermatology therapeutic platform rather than selling commercialized end products.
Differentiator
Problem solved
Functional benefit
Products and services
- Antibody-targeted photo-immunotherapy platform A biotechnology platform combining antibody targeting with photo-immunotherapy for the treatment of inflammatory skin disorders, positioned for healthcare providers and pharmaceutical partners in dermatology therapeutics.
Companies that use Nira Biosciences
Customer profileSegments1 record
Ideal customer profiles1 record
Nira Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Nira Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Alys PharmaceuticalscoreNirabio is now a fully owned subsidiary of Alys Pharmaceuticals. The company maintains its identity as Nirabio while operating under the Alys Pharmaceuticals corporate umbrella.
Nira Biosciences competitors and assessment
Company assessmentDirect peers
- AnaptysBio: AnaptysBio is an immunology-focused biotechnology company developing antibody therapeutics for inflammatory and autoimmune diseases. It is comparable to Nira as an antibody-platform biotech targeting inflammation, with overlapping therapeutic areas in dermatology and immunology.
- Alys Pharmaceuticals: Alys Pharmaceuticals is the parent company that has fully acquired Nira Biosciences. It is directly comparable because it operates in the same antibody-targeted photo-immunotherapy space for inflammatory skin disorders and is the entity through which Nira's assets are now being advanced.
- Union Therapeutics: Union Therapeutics is a biotechnology company developing innovative treatments for inflammatory skin diseases including atopic dermatitis. It is comparable to Nira as a specialty biotech focused specifically on novel mechanisms for inflammatory skin disorders.
- MoonLake Immunotherapeutics: MoonLake is a clinical-stage immunology biotech developing biologic therapies (e.g., sonelokimab) for inflammatory skin and joint diseases. It is comparable to Nira as a focused inflammation dermatology biotech building differentiated therapeutic platforms for skin disorders.
Emerging players
- Dermavant Sciences: Dermavant is a specialty biopharmaceutical company developing treatments for inflammatory skin diseases, including novel topical and systemic therapies. It is comparable to Nira as a focused emerging player in inflammatory dermatology, though it relies on more conventional modalities.
Broad incumbents
- Amgen: Amgen markets Otezla and Tezspire and has a broader inflammation pipeline including antibodies relevant to atopic dermatitis and other skin conditions. It is comparable as a broad incumbent antibody developer with overlapping inflammatory skin disease ambitions.
- Sanofi (Dupixent / anti-IL-4Rα franchise): Sanofi, with Regeneron, markets Dupixent, the leading biologic for atopic dermatitis and other inflammatory skin and respiratory conditions. It is comparable as the dominant incumbent in antibody-based inflammatory skin therapeutics and defines the competitive benchmark Nira must beat.
- AbbVie (Rinvoq / Skyrizi): AbbVie markets Rinvoq (JAK inhibitor) and Skyrizi (anti-IL-23) for inflammatory skin diseases including psoriasis and atopic dermatitis. It is comparable as a broad incumbent immunology company whose dermatology franchise sets the standard-of-care against which Nira's platform would compete.
- Novartis (Cosentyx): Novartis markets Cosentyx (secukinumab), an anti-IL-17 antibody widely used in psoriasis and other inflammatory skin conditions. It is comparable as a broad incumbent with a large antibody franchise in inflammatory dermatology.
- Eli Lilly (Olumiant / lebrikizumab program): Eli Lilly has been active in inflammatory skin disease therapeutics, including Olumiant (baricitinib) and the lebrikizumab anti-IL-13 program for atopic dermatitis. It is comparable as a large incumbent developing antibody-based therapeutics in the same inflammatory dermatology space.
Market position
Customer concentration
Nira Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nira Biosciences leadership team
Management profileNumber of profiles
Profiles1 record
Nira Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nira Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nira Biosciences
What does Nira Biosciences do?
Nira Biosciences develops a biotechnology platform for antibody-targeted photo-immunotherapy treatments aimed at inflammatory skin disorders. The platform combines antibody targeting with photo-immunotherapy to deliver therapeutic intervention for dermatologic inflammatory conditions. As a fully owned subsidiary of Alys Pharmaceuticals, the company focuses on advancing this single-indication dermatology therapeutic platform rather than selling commercialized end products.
Is Nira Biosciences a public or private company?
Nira Biosciences is a private company. It is classified as corporate owned and is currently acquired.
When was Nira Biosciences founded?
Nira Biosciences was founded in -1.
Who are Nira Biosciences's main competitors?
Direct peers on record are AnaptysBio, Alys Pharmaceuticals, Union Therapeutics and MoonLake Immunotherapeutics. Dermavant Sciences is listed as an emerging player. Broad incumbents are Amgen, Sanofi (Dupixent / anti-IL-4Rα franchise), AbbVie (Rinvoq / Skyrizi), Novartis (Cosentyx) and Eli Lilly (Olumiant / lebrikizumab program).
Does Nira Biosciences have an API?
No public API is recorded for Nira Biosciences.
What industry is Nira Biosciences in?
Nira Biosciences's product category is Dermatology Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.